Shares of Elicio Therapeutics Inc. (ELTX) touched a new high of $12.42 in early trading today, as investors await a major clinical trial milestone in the coming months, particularly in the fourth quarter.
Elicio is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. Its lead investigational asset is ELI-002, a lymph node-targeted mutant Kristen rat sarcoma (mKRAS) cancer vaccine.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.